[Encapsulated ANP cDNA transfection cells attenuate hypertension in hypertensive rats].
OBJECTIVE
We Investigated a gene therapy delivery system based on microcapsules enclosing recombinant Chinese hamster ovary (CHO) cells engineered to secrete a therapeutic peptide-atrial natriuretic peptide (ANP).


METHODS
Human atrial natriuretic peptide gene transfecting Chinese hamster ovary (CHO) cells were encapsulated in non-antigenic biocompatible polycaprolactone (PCL) capsules prior to their implantation into rats, then, the PCL-tubes were implanted into hypertensive DSS rats intraperitoneally.


RESULTS
The PCL-tubes 2 d post implantation caused a significant delay of blood pressure increase. The effect lasted for more than 5 months. The PCL-tubes also caused significant increases in renal blood flow, glomerular filtration rate, sodium output, urine excretion. Plasma levels of ANP in rats implanted with the PCL-tubes containing engineering cells is higher than that of the control rats.


CONCLUSIONS
This study demonstrates encapsulated engineering cells have significant potential in treatment of hypertension.
Chen
Li-guo
LG
Qu
Yi
Y
Peng
Wen-zhen
WZ
Wang
Yue-qi
YQ
Xiao
Jing
J
Wang
Zheng-rong
ZR
D000818:Animals; D009320:Atrial Natriuretic Factor / Q000235:genetics* / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D016466:CHO Cells; D006224:Cricetinae; D004339:Drug Compounding; D016503:Drug Delivery Systems; D004341:Drug Evaluation; D015316:Genetic Therapy / Q000379:methods*; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D011091:Polyesters; D051381:Rats; D014162:Transfection
D011091:Polyesters; C016240:polycaprolactone; D009320:Atrial Natriuretic Factor